Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec
